Ghrelin and motilin receptor agonists: Time to introduce bias into drug design

Neurogastroenterology and Motility

Volumn 26, Issue 2, 2014, Pages 149-155

  Sanger, G J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Camicinal GSK962040; Constipation; Gastroparesis; Ghrelin; Motilin; Ulimorelin

Indexed keywords

CAMICINAL; GHRELIN; MOTILIN; MOTILIN RECEPTOR AGONIST; RQ 00201894; UNCLASSIFIED DRUG;

CONSTIPATION; DRUG DESIGN; DRUG SELECTIVITY; GASTROINTESTINAL DISEASE; HUMAN; NAUSEA; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING; STOMACH MOTILITY; STOMACH PARESIS; UPPER GASTROINTESTINAL TRACT;

CAMICINAL/GSK962040; CONSTIPATION; GASTROPARESIS; GHRELIN; MOTILIN; ULIMORELIN;

ANIMALS; DRUG DESIGN; GASTROINTESTINAL MOTILITY; HUMANS; RATS; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GHRELIN; RECEPTORS, NEUROPEPTIDE;

EID: 84892640469     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12300     Document Type: Review

References (52)

1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
2. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85: 495-522.
3. Peeters T, Matthijs G, Depoortere I, Cachet T, Hoogmartens J, Vantrappen G. Erythromycin is a motilin receptor agonist. Am J Physiol 1989; 257: G470-4.
4. Feighner SD, Tan CP, McKee KK, Palyha OC, Hreniuk DL, Pong SS, Austin CP, Figueroa D et al. Receptor for motilin identified in the human gastrointestinal system. Science 1999; 284: 2184-8.
5. McCallum RW, Lembo A, Esfandyari T, Bhandari BR, Ejskjaer N, Cosentino C, Helton N, Mondou E et al. The TZP-102 Phase 2b Study Group. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013; 25: e705-17.
6. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010; 9: 203-14.
7. Pustovit RV, Callaghan B, Kosari S, Rivera LR, Thomas H, Brock JA, Furness JB. The mechanism of enhanced defecation caused by the ghrelin receptor agonist, ulmorelin. Neurogastroenterol Motil 2013; doi: 10:1111/nmo.12259.
8. Shimizu Y, Chang EC, Shafton AD, Sanger GJ, Witherington J, Furness JB. Evidence that stimulation of ghrelin receptors in the spinal cord initiates propulsive activity in the colon of the rat. J Physiol 2006; 576.1: 329-38.
9. Ferens DM, Yin L, Bron R, Hunne B, Ohashi-Doi K, Kitchener PD, Sanger GJ, Witherington J et al. Functional and in situ hybridisation evidence that preganglionic sympathetic vasoconstrictor neurons express ghrelin receptors. Neuroscience 2010; 166: 671-9.
10. Dass NB, Hill J, Muir A, Testa T, Wise A, Sanger GJ. The rabbit motilin receptor: molecular characterisation and pharmacology. Br J Pharmacol 2003; 140: 948-54.
11. Broad J, Mukherjee S, Samadi M, Martin JE, Dukes GE, Sanger GJ. Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br J Pharmacol 2012; 167: 763-74.
12. Folwaczny C, Chang JK, Tschöp M. Ghrelin and motilin: two sides of one coin? Eur J Endocrinol 2001; 144: R1-3.
13. Sanger GJ, Holbrook JD, Andrews PLR. The translational value of rodent gastrointestinal functions: a cautionary tale. Trends Pharmacol Sci 2011; 32: 402-9.
14. Sanger GJ. Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases. Drug Discov Today 2008; 13: 234-9.
15. Ang DC, Nicolai H, Vos R, Berghe PV, Sifrim D, Depoortere I, Peeters TL, Janssens J et al. Gastric Phase 3 is a hunger signal in the interdigestive state in man. Gastroenterol 2008; 134(4, S1): A-314.
16. Sanger GJ, Wang Y-T, Hobson A, Broad J. Motilin: toward a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists. Br J Pharmacol 2013; 170: 1349-62.
17. Camilleri M, Papathanasopoulos A, Odunsi ST. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 2009; 6: 343-52.
18. Alexander SPH, Mathie A, Peters JA. Guide to receptors and channels (GRAC), 5th edn. Br J Pharmacol 2011; 164(Suppl. 1): S1-324.
19. Westaway SM, Sanger GJ. The identification and rationale for drugs which act at the motilin receptor. Prog Med Chem 2009; 48: 31-80.
20. Broad J, Sanger GJ. The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. Br J Pharmacol 2013; 168: 1859-67.
21. Utsunomiya S, Matsuura B, Ueda T, Miyake T, Furukawa S, Kumagi T, Ikeda Y, Abe M et al. Critical residues in the transmembrane helical bundle domains of the human motilin receptor for erythromycin binding and activity. Regul Pept 2013; 180: 17-25.
22. Mitselos A, Depoortere I, Peeters TL. Delineation of the motilin domain involved in desensitization and internalization of the motilin receptor by using full and partial agonists. Biochem Pharmacol 2007; 73: 115-24.
23. Kenakin TP. Perspectives in pharmacology: functional selectivity and biased receptor signalling. J Pharmacol Exp Ther 2011; 336: 296-302.
24. Jarvie EM, North Laidler V, Corcoran S, Bassil A, Sanger GJ. Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro. Br J Pharmacol 2007; 150: 455-62.
25. Tack J, Peeters T. What comes after macrolides and other motilin stimulants? Gut 2001; 49: 317-8.
26. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993; 88: 203-7.
27. Boivin MA, Carey MC, Levy H. Erythromycin accelerates gastric emptying in a dose-response manner in healthy subjects. Pharmacotherapy 2003; 23: 5-8.
28. O'Grady G, Angeli TR, Du P, Lahr C, Lammers WJ, Windsor JA, Abell TL, Farrugia G et al. Abnormal initiation and conduction of slow-wave activity in gastroparesis, defined by high-resolution electrical mapping. Gastroenterol 2012; 143: 589-98.
29. McNearney TA, Sallam HS, Hunnicutt SE, Doshi D, Wollaston DE, Mayes MD, Chen JD. Gastric slow waves, gastrointestinal symptoms and peptides in systemic sclerosis patients. Neurogastroenterol Motil 2009; 21: 1269-78.
30. Sivertsen B, Lang M, Frimurer TM, Holliday ND, Bach A, Els S, Engelstoft MS, Petersen PS et al. Unique interaction pattern for a functionally biased ghrelin receptor agonist. J Biol Chem 2011; 286: 20845-60.
31. Sivertsen B, Holliday N, Madsen AN, Holst B. Functionally biased signaling properties of 7TM receptors - Opportunities for drug development for the ghrelin receptor. Br J Pharmacol 2013; 170: 1349-62.
32. Sakata I, Yamazaki M, Inoue K, Hayashi Y, Kangawa K, Sakai T. Growth hormone secretagogue receptor expression in the cells of the stomach-projected afferent nerve in the rat nodose ganglion. Neurosci Lett 2003; 342: 183-6.
33. Fukuda H, Mizuta Y, Isomoto H, Takeshima F, Ohnita K, Ohba K, Omagari K, Taniyama K et al. Ghrelin enhances gastric motility through direct stimulation of intrinsic neural pathways and capsaicin-sensitive afferent neurones in rats. Scand J Gastroenterol 2004; 12: 1209-14.
34. Page AJ, Slattery JA, Milte C, Laker R, O'Donnell T, Dorian C, Brierley SM, Blackshaw LA. Ghrelin selectively reduces mechanosensitivity of upper gastrointestinal vagal afferents. Am J Physiol 2007; 292: G1376-84.
35. le Roux CW, Neary NM, Halsey TJ, Small CJ, Martinez-Isla AM, Ghatei MA, Theodorou NA, Bloom SR. Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J Clin Endocrinol Metabol 2005; 90: 4521-4.
36. Rudd JA, Ngan MP, Wai MK, King AG, Witherington J, Andrews PL, Sanger GJ. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett 2006; 392: 79-83.
37. Hejazi RA, Lavenbarg TH, McCallum RW. Elevated serum ghrelin levels in adult patients with cyclic vomiting syndrome. Am J Gastroenterol 2011; 106: 1858-9.
38. Oruç AS, Mert I, Akturk M, Aslan E, Polat B, Buyukkagnici U, Danişman N. Ghrelin and motilin levels in hyperemesis gravidarum. Arch Gynecol Obstet 2013; 287: 1087-92.
39. Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, Frost GS, Ghatei MA et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 1994; 89: 2832-6.
40. Hiura Y, Takiguchi S, Yamamoto K, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Miyata H et al. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer 2012; 118: 4785-94.
41. Ejskjaer N, Dimcevski G, Wo J, Hellström PM, Gormsen LC, Sarosiek I, Søfteland E, Nowak T et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol Motil 2010; 22: 1069-81.
42. Sanger GJ, Westaway SM, Barnes AA, Macpherson DT, Muir AI, Jarvie EM, Bolton VN, Cellek S et al. GSK962040A: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol Motil 2009; 21: 657-66.
43. Dukes GE, Barton M, Dewit O, Stephens K, Vasist L, Young M, Richards D, Alpers D et al. Safety/tolerability, pharmacokinetics (PK), and effect on gastric emptying(GE) with 14-days repeat oral dosing of the motilin receptor agonist, GSK962040, in healthy male and female volunteers. Neurogastroenterol Motil 2010; 22(S1): 14-5.
44. Hellstrom PM, Tack JF, Stephens KE, Barton ME, Vasist LS, Richards DB, Williams PM, Alpers DH et al. A double-blind, randomized placebo-controlled phase II study of the pharmacokinetics of single doses of the motilin agonist GSK962040, in patients with type I diabetes mellitus (TIDM) and gastroparesis. Gastroenterol 2011; 140: S183.
45. Chapman M, Fraser R, Nguyen N, Deane A, O'Connor S, Richards D, Hacquoil K, Vasist L et al. The effect of GSK962040, a selective motilin agonist, on gastric emptying in critically ill patients with enteral feed intolerance. Crit Care Med 2011; 39: 195.
46. Takahashi N, Koba N, Yamamoto T, Sudo M. Characterization of a novel, potent, and selective small molecule motilin receptor agonist, RQ-00201894. Gastroenterol 2010; 138(Suppl 1): S-713.
47. Camilleri M, Acosta A. A ghrelin agonist fails to show benefit in patients with diabetic gastroparesis: let's not throw the baby out with the bath water. Neurogastroenterol Motil 2013; 25: 859-63.
48. Sanger GJ, Alpers D. Development of drugs for gastrointestinal motor disorders: translating science to clinical need. Neurogastroenterol Motil 2008; 20: 177-84.
49. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013; 108: 18-37.
50. Coulie B, Camilleri M. Intestinal pseudo-obstruction. Annu Rev Med 1999; 50: 37-55.
51. Broad J, Kung VW, Boundouki G, Aziz Q, De Maeyer JH, Knowles CH, Sanger GJ. Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotility. Br J Pharmacol 2013; 170: 1253-61.
52. Holst B, Mokrosinski J, Lang M, Brandt E, Nygaard R, Frimurer TM, Beck-Sickinger AG, Schwartz TW. Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem 2007; 282: 15799-811.